Enovis(US:ENOV)2025-05-08 11:17Financial Performance - Reported sales growth of +8% and comparable constant currency growth of +10%[8, 18] - Adjusted gross margin expanded by +300 basis points, driven by product mix and EGX efficiency improvements[18] - Adjusted EBITDA margin expanded by +160 basis points due to Recon mix and operating leverage[8, 18] - Q1 2025 net sales reached $559 million compared to $516 million in Q1 2024[16] - Adjusted EPS increased to $0.81 in Q1 2025 from $0.50 in Q1 2024[16] Segment Performance - Reconstructive segment sales grew by +11% year-over-year, with +13% comparable growth[10] - Prevention & Recovery (P&R) segment sales grew by +5% year-over-year, with +8% comparable growth[13] - International reconstructive segment experienced comparable growth of +14% xFx[11] Outlook and Tariffs - Full year 2025 revenue outlook revised to $2.22-$2.25 billion[19] - Full year 2025 adjusted EBITDA outlook revised to $385-$395 million[19] - Expects a $20 million EBITDA headwind due to tariffs, equally spread across Q3 and Q4[22, 27]